Philip Borden

Engages in healthcare industry focusing on biotechnology

Acts as Venture Capital Fund

The private company is based in Boston. The organization focuses on education, outreach, advocacy, and clinical research initiatives to improve quality of life and empower the mitochondrial disease community. MitoAction offers resources on diagnosis, symptoms, treatment options—including evolving therapies and clinical trials—and daily disease management. Specialized support programs include Mito411, confidential support groups, and community-building activities. The organization hosts educational events, expert series, webinars, and conferences to raise awareness and funds. Collaborations with medical and research communities provide access to expert care and clinical guidelines. Additional services include patient and family support programs, scholarships, advocacy initiatives, and resources for travel accommodations and care coordination. MitoAction is a nonprofit organization founded in 2005 that supports children, adults, and families affected by mitochondrial disease and related metabolic disorders such as fatty acid oxidation disorders.

Rents office space and laboratory incubator for biotechnology and life science start-ups

Galen Management invests in companies located in the United States with revenues of USD 10 - 100 million and EBITDA of USD 0 - 9 million. The firm focuses on the health sector. It participates in growth capital requirements with an investment size of USD 10 - 100 million and also acquires minority or majority stakes.

Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations.

Operates as a bioanalytical laboratory for testing of new therapies to all phases of drug development for pharmaceutical and biotechnology organizations

Provides enterprise risk, compliance and quality management software solutions

Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements.